AY20 Stock Overview
Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Aytu BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.82 |
| 52 Week High | US$3.04 |
| 52 Week Low | US$2.40 |
| Beta | -1.26 |
| 1 Month Change | -6.00% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -2.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| AY20 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 6.8% | 3.8% | 1.9% |
| 1Y | n/a | -25.3% | 4.6% |
Return vs Industry: Insufficient data to determine how AY20 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how AY20 performed against the German Market.
Price Volatility
| AY20 volatility | |
|---|---|
| AY20 Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AY20 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AY20's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 150 | Josh Disbrow | aytubio.com |
Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.
Aytu BioPharma, Inc. Fundamentals Summary
| AY20 fundamental statistics | |
|---|---|
| Market cap | €16.03m |
| Earnings (TTM) | -€16.71m |
| Revenue (TTM) | €91.46m |
0.2x
P/S Ratio-1.0x
P/E RatioIs AY20 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AY20 income statement (TTM) | |
|---|---|
| Revenue | US$98.50m |
| Cost of Revenue | US$36.20m |
| Gross Profit | US$62.29m |
| Other Expenses | US$80.29m |
| Earnings | -US$18.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -3.23 |
| Gross Margin | 63.24% |
| Net Profit Margin | -18.27% |
| Debt/Equity Ratio | 48.7% |
How did AY20 perform over the long term?
See historical performance and comparison